.CLARK et al.

U.S. National Phase of PCT/GB2004/004392

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) A compound of formula (I):

$$\mathbb{R}^{5}$$
 \mathbb{R}^{2}
 \mathbb{R}^{3}
 \mathbb{R}^{1}
 \mathbb{R}^{3}
 \mathbb{R}^{3}
 \mathbb{R}^{1}
 \mathbb{R}^{3}

or a salt, solvate and chemically protected form thereof, wherein: one of \mathbb{R}^2 and \mathbb{R}^5 is:

- (i) H or an optionally substituted C₁₋₄ alkyl group; or
- (ii)an optionally substituted C_{5-7} aryl; and the other of R^2 and R^5 is the other group; m and n can be 0 or 1, and m + n = 1 or 2

R^N is H or optionally substituted C₁₋₄ alkyl

R³ is either:

- (i) carboxy;
- (ii) a group of formula (II):

(iii) a group of formula (III):

.CLARK et al.

U.S. National Phase of PCT/GB2004/004392

$$-\overset{O}{\underset{O}{\overset{\parallel}{=}}}\overset{O}{\underset{H}{\overset{\vee}{=}}}\overset{R}{\underset{R}{\overset{\vee}{=}}}$$
 (III)

wherein R is optionally substituted C_{1-7} alkyl, C_{5-20} aryl, or $NR^{N3}R^{N4}$, where R^{N3} and R^{N4} are independently selected from optionally substituted C_{1-4} alkyl; or

- (iv) tetrazol-5-yl.
- 2. (original) A compound according to claim 1, wherein R^5 is the optionally substituted C_{5-7} aryl group and R^2 is H or the optionally substituted C_{1-4} alkyl group.
- 3. (original) A compound according to claim 2, wherein R^2 is selected from H or an optionally substituted C_{1-3} alkyl group.
- 4. (original) A compound according to claim 3, wherein R² is a methyl group.
- 5. (currently amended) A compound according to any one of claims 2 to 4 claim 2, wherein R^5 is a C_6 aryl group.
- 6. (original) A compound according to claim 5, wherein R⁵ is preferably phenyl.

.CLARK et al.

U.S. National Phase of PCT/GB2004/004392

- 7. (currently amended) A compound according to any one of the preceding claims claim 1 wherein the C_{5-7} aryl group is substituted by substituents selected from C_{1-7} alkoxy groups.
- 8. (currently amended) A compound according to any one of the preceding claims claim 1 wherein R³ is either:
- (i) a group of formula (II):

(ii) a group of formula (III):

- 9. (original) A compound according to claim 8, wherein R is selected from an optionally substituted C_{5-20} aryl group, and an optionally substituted C_{5-20} aryl- C_{1-7} alkyl group.
- 10. (original) A compound according to claim 8, wherein R is a $C_{\text{1-7}}$ alkyl group.

,CLARK et al.

U.S. National Phase of PCT/GB2004/004392

- 11. (currently amended) A compound according to any one of the preceding claims $\frac{1}{n}$, wherein n + m = 1.
- 12. (original) A compound according to claim 11, wherein n is 0 and m is 1.
- 13. (currently amended) A compound according to any one of the preceding claims claim 1, wherein R^N is H or methyl.
- 14. (currently amended) The use of a compound according to any one of claims 1 to 13 claim 1 or a pharmaceutically acceptable salt thereof in a method of therapy.
- 15. (currently amended) A pharmaceutical composition comprising a compound according to any one of claims 1 to 13 claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
- 16. (currently amended) The use of a compound according to any one of claims 1 to 13 claim 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of a condition alleviated by antagonism of an EP₄ receptor.
- 17. (original) The use according to claim 16, wherein the condition which can be alleviated by antagonism of an EP₄ receptor is a primary headache disorder.

"CLARK et al. U.S. National Phase of PCT/GB2004/004392

18. (original) The use according to claim 17, wherein the primary headache disorder is a migraine.